Moxifloxacin-d5

Moxifloxacin-d5 (BAY 12-8039-d5 (free base) ) is deuterium labeled Moxifloxacin. Moxifloxacin is an orally active 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia[1][2].

Product Specifications

CAS Number

[1092356-43-8]

Product Name Alternative

BAY 12-8039-d5 (free base)

UNSPSC

12352005

Target

Antibiotic; Bacterial; Isotope-Labeled Compounds

Related Pathways

Anti-infection; Others

Applications

COVID-19-immunoregulation

Field of Research

Infection; Cancer

Smiles

COC1=C2N(C3([2H])C([2H])([2H])C3([2H])[2H])C=C(C(C2=CC(F)=C1N4C[C@@]5([H])[C@@](NCCC5)([H])C4)=O)C(O)=O

Molecular Formula

C21H19D5FN3O4

Molecular Weight

406.46

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Culley, C.M., et al., Moxifloxacin: clinical efficacy and safety. Am J Health Syst Pharm, 2001. 58 (5) : p. 379-88.|[3]Balfour JA, et al. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs. 2000 Jan;59 (1) :115-39.|[4]Grayo S, et al. Comparison of the in vitro efficacies of moxifloxacin and amoxicillin against Listeria monocytogenes. Antimicrob Agents Chemother. 2008 May;52 (5) :1697-702.|[5]Ioannidis O, et al. Effect of moxifloxacin on survival, lipid peroxidation and inflammation in immunosuppressed rats with soft tissue infection caused by Stenotrophomonas maltophilia. Microbiol Immunol. 2014 Feb;58 (2) :96-102.